Egis Pharmaceuticals made a net profit of HUF 18,531 mil in 2012, up 36.4% when compared to the last year. Total sales reached HUF 132,825 mil, which is up 3.01% when compared to the previous year.
Historically, the company’s net profit reached an all time high of HUF 18,531 mil in 2012 and an all time low of HUF 5,540 mil in 2003.
In terms of sales, Egis Pharmaceuticals reached an all time high of HUF 132,825 mil in 2012 and an all time low of HUF 71,728 mil in 2001.
Egis Pharmaceuticals's net profit has grown 19.4% a year on average in the last five years while sales have increased by 2.54% a year since 2007.
The firm generated its shareholders an average return on invested capital of 12.8% in the last five years.
As far as Egis Pharmaceuticals's peers are concerned, Gedeon Richter posted a net profit and sales of HUF 49,265 mil and HUF 326,702 mil in 2012, Krka generated a net profit of HUF 160 mil (with sales of HUF 1,143 mil) and Sanofi-Aventis Czech Republic netted HUF 45.2 mil (sales of HUF 7,225 mil).